Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.

Hormone research - 1 Jan 2008

Padidela Raja, Camacho-Hübner Cecilia, Attie Kenneth M, Savage Martin O

Abstract excerpt

Noonan syndrome (NS) is a phenotypically heterogeneous syndrome which is frequently associated with short stature. Recent genetic investigations have identified mutations in five genes, namely PTPN11, KRAS, SOS1, NF1 and RAF1 in patients with the NS phenotype. PTPN11 is the commonest, being present in approximately 50% of cases. The degree of short stature in children does not associate closely with the presence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Height
Share to RAF1 gene
Share to Growth Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Human Growth Hormone

Share to Insulin-Like Growth Factor I

Share to Mutation

Share to Noonan Syndrome

Share to Recombinant Proteins

Source

Identifiers

PMID: 18663312
DOI: 10.1159/000145016

Genes

PTPN11
KRAS
RAF1
SOS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.PMID 18663312Read ↗

Abnormal growth in noonan syndrome: the challenge of optimal therapy.Semantic proximity Read ↗

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.Semantic proximity Read ↗

[Noonan syndrome: from phenotype to growth hormone therapy].Semantic proximity Read ↗

PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

Short stature and its treatment in Turner and Noonan syndromes.Semantic proximity Read ↗

GH therapy in Noonan syndrome: Review of final height data.Semantic proximity Read ↗

Noonan syndrome: relationships between genotype, growth, and growth factors.Semantic proximity Read ↗

Growth patterns of patients with Noonan syndrome: correlation with age and genotype.Semantic proximity Read ↗

Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort.Semantic proximity Read ↗

Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.Semantic proximity Read ↗

Noonan syndrome, the Ras-MAPK signalling pathway and short stature.Semantic proximity Read ↗

Noonan syndrome: rhGH treatment and PTPN11 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.